Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

bmiMD vs Defy Medical

An in-depth comparison of two leading GLP-1 Providers

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
bmiMD logo

bmiMD

9.1
★★★★4.6/5

Best for: starting below a standard dose, with microdose tiers

Visit bmiMD
VS
Defy Medical logo

Defy Medical

4.1
★★☆☆☆2.1/5
Visit Defy Medical

Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, bmiMD starts at $99/mo, and bmiMD finishes ahead, 9.1 to 4.1. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.

Pricing

bmiMD

Compounded semaglutide injection (all doses, flat)Compounded
$99/mo
semaglutide

Ladder by plan length: 12 mo $99/mo (Total $1,188.00), 6 mo $109/mo, 3 mo $119/mo, 1 mo $129/mo. 'Same price at every dose'; provider visit + free shipping included. Verified 2026-07-14 at bmimd.com/personalized-glp-1/ and /semaglutide-injection/.

Compounded tirzepatide injection (all doses, flat)Compounded
$139/mo
tirzepatide

Ladder by plan length: 12 mo $139/mo (Total $1,668.00), 6 mo $149/mo, 3 mo $159/mo, 1 mo $179/mo. Same flat-dose model. Verified 2026-07-14 at bmimd.com/tirzepatide-injection/.

Semaglutide Microdose (new product line)Compounded
$99/mo
semaglutide

Strike-through pricing shown: $151.20 -> $99/mo (12-mo) up to $199.80 -> $129/mo (monthly), labeled 'Limited time offer'. bmimd.com/glp-1-microdose/.

Tirzepatide Microdose (new product line)Compounded
$139/mo
tirzepatide

Strike-through pricing shown: $250.20 -> $139/mo (12-mo) up to $299.70 -> $179/mo (monthly), labeled 'Limited time offer'. bmimd.com/glp-1-gip-microdose/.

Defy Medical

Pricing not publicly listed.

What’s included

bmiMD

Covered by the monthly price

Medication

In the price

Clinician visits

In the price

Shipping

In the price

Lab work

Not stated

Coaching

Not stated

Defy Medical

Inclusions not disclosed.

Score breakdown

Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.

bmiMD

9.1/10

Overall

Defy Medical

4.1/10

Value25%

9.7A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
5.0

User Experience15%

8.0A
vs
B
3.0

Trust & Safety15%

8.5A
vs
B
4.0

Accessibility10%

10.0A
vs
B
5.0

Support10%

7.0A
vs
B
5.0

Features & Coverage

FeaturebmiMDDefy Medical
Starting Price$99/mo
Features2 features8 features
States Available50Not disclosed
Compounded✓ Yes
Brand Name
FSA/HSA Accepted
FDA WarningsNoneNone

About bmiMD

bmiMD is a medical weight loss clinic that prescribes GLP-1 medications through telehealth.

Read our full bmiMD review →

About Defy Medical

Neither a price nor a list of covered states appears online. Hormone replacement made Defy Medical's name over many years, but the clinic writes GLP-1s too: semaglutide and tirzepatide as weekly shots, as orally disintegrating tablets and as liquid drops, with liraglutide taken daily by injection. Those drops and ODTs exist for patients who will not self-inject, or who live where shipping an injectable is restricted. Consults go deep, blood testing is comprehensive, and phlebotomy can come to you. Dr. Justin Saya is medical director.

Read our full Defy Medical review →

Pros & Cons

bmiMD

What we like

  • Semaglutide at $99 a month, 48% below the $189 median for the same drug and form across this register
  • Tirzepatide at $139 a month, 48% below the $267 median for the same drug and form across this register
  • Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
  • The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
  • The monthly figure covers medication, consult, shipping
  • Coverage is published for all 50 states
  • No FDA warning letter matched this operator when we searched our enforcement register

Watch-outs

  • No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

Defy Medical

What we like

  • No FDA warning letter matched this operator when we searched our enforcement register

Watch-outs

  • No price appears until the medical intake is complete, so the cost cannot be compared before health information is submitted
  • No state list is on record here, so whether it serves your state cannot be confirmed from this page
  • No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here

Our Verdict

Winner: bmiMD

bmiMD takes it, 9.1 against 4.1, and it is especially strong on starting below a standard dose, with microdose tiers. Defy Medical is no weak second.

Choose bmiMD if…

You want starting below a standard dose, with microdose tiers and an opening price near $99 a month.

Choose Defy Medical if…

You want broader feature coverage.

Ready to start? Vetted GLP-1 providers

Vetted telehealth providers that prescribe GLP-1 online.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.3

Telos Rx

Starting below a standard dose, with microdose tiers

7.0

MyDrHank

An oral route if you will not self-inject

6.0

SkinnyRx

Starting below a standard dose, with microdose tiers

bmiMD vs Defy Medical: FAQ

Glossary

The words sellers use, defined. Tap any term.

Continue exploring bmiMD and Defy Medical head-to-heads in the same category.

Or see the full category ranking.

Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.